Kousaku Ohinata

Kousaku Ohinata

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
Naohisa ShobakoNaohisa Shobako
Naohisa Shobako
YOYutaro Ogawa
Yutaro Ogawa
AIAtsushi Ishikado
Atsushi Ishikado
KHKayo Harada
Kayo Harada
EKEtsuko Kobayashi
Etsuko Kobayashi
KOKousaku Ohinata
Kousaku Ohinata

15 February 2012 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
YYYuko Yamada
Yuko Yamada
AMAya Muraki
Aya Muraki
MOMariko Oie
Mariko Oie
NKNorimasa Kanegawa
Norimasa Kanegawa
AOAyako Oda
Ayako Oda
KOKousaku Ohinata
Kousaku Ohinata
Soymorphin-5 (YPFVV) derived from soybean β-conglycinin β-subunit is a μ-opioid agonist peptide having anxiolytic-like activity. Here, we show that soymorphin-5 improves glucose and lipid metabolism after long-term oral administration to KKAy mice, a type 2 diabetes model animal. Soymorphin-5 inhibited hyperglycemia without an increase in plasma insulin levels in KKAy mice. Soymorphin-5 also decreased plasma and liver triglyceride (TG) levels and liver weight, suggesting that soymorphin-5 improved lipid metabolism. Soymorphin-5 increased plasma adiponectin concentration and liver mRNA expression of AdipoR2, a subtype of adiponectin receptor that is involved in stimulating the peroxisome proliferator-activated receptor (PPAR)α pathway and fatty acid β-oxidation. The expressions of the mRNA of PPARα and its target genes acyl-CoA oxidase, carnitine palmitoyltransferase 1 A, and uncoupling protein-2, in the liver were also increased after oral administration of soymorphin-5. Furthermore, des-Tyr-soymorphin-5 (PFVV) without μ-opioid and anxiolytic-like activities did not decrease blood glucose levels in KKAy mice. These results suggest that μ-opioid peptide soymorphin-5 improves glucose and lipid metabolism via activation of the adiponectin and PPARα system and subsequent increases of β-oxidation and energy expenditure in KKAy mice.

1 September 2010 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
KKKentaro Kaneko
Kentaro Kaneko
MIMasashi Iwasaki
Masashi Iwasaki
MYMasaaki Yoshikawa
Masaaki Yoshikawa
KOKousaku Ohinata
Kousaku Ohinata
We previously reported that soymorphins, μ-opioid agonist peptides derived from soy β-conglycinin β-subunit, have anxiolytic-like activity. The aim of this study was to investigate the effects of soymorphins on food intake and gut motility, along with their mechanism. We found that soymorphins decreases food intake after oral administration in fasted mice. Orally administered soymorphins suppressed small intestinal transit at lower dose than that of anorexigenic activity. Suppression of food intake and small intestinal transit after oral administration of soymorphins was inhibited by naloxone or naloxonazine, antagonists of μ- or μ1-opioid receptor, respectively, after oral but not intraperitoneal administration. The inhibitory activities of small intestinal transit by soymorphins were also inhibited by WAY100135, raclopride, or saclofen, antagonists for serotonin 5-HT1A, dopamine D2, or GABABreceptor, respectively. We then examined the order of activation of 5-HT1A, D2, and GABABreceptors, using their agonists and antagonists. The inhibitory effect of 8-hydroxy-2-dipropylaminotetralin hydrobromide, a 5-HT1Aagonist, after oral administration on small intestinal transit was blocked by raclopride or saclofen. Bromocriptine, a D2agonist-induced small intestinal transit suppression, was inhibited by saclofen, but not by WAY100135. Baclofen, a GABABagonist-induced small intestinal transit suppression, was not blocked by WAY100135 or raclopride. These results suggest that 5-HT1Aactivation elicits D2followed by GABABactivations in small intestinal motility. We conclude that orally administered soymorphins suppress food intake and small intestinal transit via μ1-opioid receptor coupled to 5-HT1A, D2, and GABABsystems.

5 February 2008 in FEBS Letters
Verified
Journal Article
Closed access
KOKousaku Ohinata
Kousaku Ohinata
KTKuniko Takagi
Kuniko Takagi
KBKyoko Biyajima
Kyoko Biyajima
YFYoko Fujiwara
Yoko Fujiwara
SFShingo Fukumoto
Shingo Fukumoto
MYMasaaki Yoshikawa
Masaaki Yoshikawa

1 March 2009 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
KOKousaku Ohinata
Kousaku Ohinata
MTMasami Takemoto
Masami Takemoto
MKMakoto Kawanago
Makoto Kawanago
SFShuya Fushimi
Shuya Fushimi
Hitoshi ShirakawaHitoshi Shirakawa
Hitoshi Shirakawa
MKMichio Komai
Michio Komai
We investigated the role of zinc in food intake regulation using rats during early-stage zinc deficiency without decreased zinc concentrations in pla

6 September 2011 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
IHI‐Ching Hou
I‐Ching Hou
CSChihiro Suzuki
Chihiro Suzuki
NKNorimasa Kanegawa
Norimasa Kanegawa
AOAyako Oda
Ayako Oda
AYAyako Yamada
Ayako Yamada
KOKousaku Ohinata
Kousaku Ohinata
J. Neurochem. (2011) 119, 785–790. β‐Lactotensin (His‐Ile‐Arg‐Leu) is a bioactive peptide derived from bovine milk β‐lactoglobulin, acting as a natural agonist for neurotensin receptors. We found that β‐lactotensin exhibited anxiolytic‐like activity in an elevated plus‐maze test after its intraperitoneal (i.p.) administration in mice. β‐Lactotensin was also orally active. The anxiolytic‐like activity of β‐lactotensin after i.p. administration was blocked by levocabastine, an antagonist for the neurotensin NTS2 receptor. β‐Lactotensin had anxiolytic‐like activity in wild‐type but not Ntsr2‐knockout mice. β‐Lactotensin increased intracellular Ca2+ flux in glial cells derived from wild‐type mice but not Ntsr2 knockout mice. These results suggest that β‐lactotensin acts as an NTS2 receptor agonist having anxiolytic‐like activity. The anxiolytic‐like activity of β‐lactotensin was also blocked by SCH23390 and SKF83566, antagonists for dopamine D1 receptor, but not by raclopride, an antagonist for D2 receptor. Taken together, β‐lactotensin may exhibit anxiolytic‐like activity via NTS2 receptor followed by D1 receptor.